D Huppe
Overview
Explore the profile of D Huppe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Welzel T, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, et al.
J Viral Hepat
. 2017 Mar;
24(10):840-849.
PMID: 28342229
Real-world studies are relevant to complement clinical trials on novel antiviral therapies against chronic hepatitis C; however, clinical practice data are currently limited. This study investigated effectiveness and safety of...
2.
Cornberg M, Petersen J, Schober A, Mauss S, Boker K, Link R, et al.
Aliment Pharmacol Ther
. 2017 Jan;
45(5):688-700.
PMID: 28078723
Background: Treatment of chronic hepatitis C genotype 3 (GT3) is more challenging compared with other genotypes. Since 2014, several new treatment regimens have been approved but sometimes based on limited...
3.
Huppe D, Buggisch P, Christensen S, Heiken H, Mauss S, Naumann U, et al.
Z Gastroenterol
. 2016 Aug;
54(8):740-7.
PMID: 27529525
In 2014, the first interferon-free treatment options for chronic Hepatitis C (CHC) became available in Europe introducing a new era of highly effective and well tolerated oral treatment options for...
4.
Riemann J, Albert J, Altenhofen L, Aschenbeck J, Dahlhoff G, Dignass A, et al.
Z Gastroenterol
. 2016 Aug;
54(3):259.
PMID: 27500297
No abstract available.
5.
Stahmeyer J, Krauth C, Bert F, Pfeiffer-Vornkahl H, Alshuth U, Huppe D, et al.
J Viral Hepat
. 2015 Sep;
23(2):105-15.
PMID: 26411532
Viral hepatitis is a major public health problem affecting millions of people worldwide. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. The aim of the study was...
6.
Mauss S, Boker K, Buggisch P, Christensen S, Hofmann W, Schott E, et al.
Z Gastroenterol
. 2015 Jul;
53(7):644-54.
PMID: 26167694
Background And Aims: The efficacy and safety of peginterferon alfa-2a (PEG-IFN) plus ribavirin (RBV) and either boceprevir (BOC) or telaprevir (TVR), and physician adherence to treatment algorithms were evaluated in...
7.
Sarrazin C, Berg T, Buggisch P, Dollinger M, Hinrichsen H, Hofer H, et al.
Z Gastroenterol
. 2015 Apr;
53(4):320-34.
PMID: 25867048
No abstract available.
8.
9.
Teich N, Helwig U, Pace A, Dignass A, Hartmann F, Huppe D, et al.
Z Gastroenterol
. 2012 Jul;
50(7):684-93.
PMID: 22760681
The treatment of patients with inflammatory bowel disease has become more complex in recent years through the introduction of various immunosuppressive agents as well as the approval of monoclonal antibodies....
10.
Mauss S, Berger F, Vogel M, Pfeiffer-Vornkahl H, Alshuth U, Rockstroh J, et al.
Z Gastroenterol
. 2012 May;
50(5):441-4.
PMID: 22581697
Chronic hepatitis C due to HCV genotype 5 and 6 infection is infrequently reported and patients are usually not included in trials. As boceprevir and telaprevir are not approved for...